BGNE240920P190000
- 2.05
- -1.48-41.93%
BeiGene Newsroom
New Additions to Roth MKM's ADR Portfolio for September
US stocks outlook: August PPI slightly lower than expected, three major futures indexes slightly lower; downgraded by major banks! Micron Technology pre-market fell more than 3%
Goldman Sachs CEO: There are signs of weakness in the job market, and the Fed may still cut interest rates by 50 basis points. UBS Group CEO: The market's expectation for a rate cut by the Fed is too aggressive, bullish on a soft landing for the US economy. Nvidia soared 8% overnight and saved the US stock market! Multiple call options made 10 times the profit.
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Beigene responds to AbbVie's lawsuit accusing it of stealing trade secrets: intending to obstruct the development process.
Beigene stated that the development of the BGB-16673 project will not be interrupted by this lawsuit.
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.
Beigene (06160.HK) denies the allegation of stealing AbbVie (ABBV.US)'s BTK degrader commercial secret.
According to the report from Interface News, beigene (06160.HK) denies the accusations made by AbbVie (ABBV.US) of stealing its BTK degrader commercial secrets. beigene will firmly defend its own intellectual property rights and mount a strong defense against the accusations launched by AbbVie. Currently, beigene is carefully reviewing AbbVie's allegations and will provide a suitable response through legal procedures.
Express News | Beigene responded to AbbVie's lawsuit: denied the allegations and will launch a strong defense.
US stocks gold rush | or become the biggest winner of the election debate! First Solar surged 15%; Is the wave of production cuts coming? The stock prices of two major lithium mining companies soared by more than 10% in response.
IBM's cloud computing business is strong, with its stock price hitting a new historical high, and has risen over 20% this year; business growth is benefiting from AI engines, with AppLovin's daily increase of 13.15%.
Express News | Stock market review of the STAR Market: Few hot spots on the market, Beigene leads the decline in pharmaceutical stocks.
Express News | The innovative drugs sector has experienced a volatile decline, with Beigene falling more than 10%.
Express News | Some China concept stocks rose against the market, beigene surged over 7%, xpeng surged nearly 5%, bilibili surged nearly 4%.
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
U.S. stock market outlook | CPI in August fell for the 5th consecutive month, with slight declines in the three major index futures; Is the "Trump trade" unraveling? Concept stocks fell before the market opens.
Apple has launched a new visual search function, and its partnership with Google is escalating; Buffett once again sells off silver! Cashing out $0.23 billion; Traders are betting that after the first 25 basis points cut by the Fed in September, there will be two more rate cuts of 50 basis points in the near future.
BeiGene Ltd. Employees Buy Shares Under Company Plan
Beigene (06160): According to the 2018 employee stock purchase plan, a total of 0.0797 million shares of American depositary shares were purchased.
Beigene (06160) announced that the subscription...
The Hang Seng Index fell 125 points, with Topsports down 16% and lithium industry stocks rebounding.
The market is waiting for US inflation data. US stock futures are soft, and Hong Kong stocks fell today. The Hang Seng Index opened 182 points lower, with the decline widening to 269 points at a low of 16,964 points. In the afternoon, the decline narrowed, with a total daily drop of 125 points or 0.7% to close at 17,108 points. The HSI Technology Index gained less than 1 point, closing at 3,450 points. The total trading volume of the market for the whole day was 105.785 billion yuan. Chinese tech stocks fell back, with Sinopec (00386.HK), CNOOC (00883.HK), and PetroChina (00857.HK) all down more than 2%.
US stocks unusual movement | Multiple bullish factors added, Beigene's pre-market rise exceeds 5%
On September 11th, BeiGene (BGNE.US) rose 5.59% in pre-market trading, reaching $208.75. In terms of news, the website of China's National Medical Products Administration Drug Evaluation Center (CDE) recently announced that the application for clinical trials of BeiGene's class 1 new drug BGB-58067 tablets has been accepted. According to publicly available information, BGB-58067 is a PRMT5 inhibitor and an investigational product for solid tumors developed by BeiGene. It is expected to enter the clinical research stage in 2024. In addition, one of the three major global oncology conferences, the European Society for Medical Oncology (ESMO), will take place on September 13th.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Abnormal movement hits directly | Stocks of innovative drugs concept are on the rise, the 2024 ESMO conference is about to be held, and institutions suggest seizing the Q3 fundamentals turning point and industry catalysis.
Innovative drug concept stocks have risen, as of press time, Beigene (06160) rose 6.97%, to HKD 124.3; Innocare-B (02162) rose 4.92%, to HKD 37.35; Innocare (09969) rose 4.91%, to HKD 5.55.